Paper41258724
Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.
Lavoie T and 5 others. Antimicrob Agents Chemother, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. Papers, record 41258724. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41258724
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ceftazidime | Major topic |
| Meropenem | Major topic |
| Enterobacter cloacae | Major topic |
| Azabicyclo Compounds | Major topic |
| Anti-Bacterial Agents | Major topic |
| Carbapenem-Resistant Enterobacteriaceae | Major topic |
| Boronic Acids | Major topic |
| Drug Combinations | |
| Microbial Sensitivity Tests | |
| Humans | |
| beta-Lactamases | |
| Bacterial Proteins | |
| Carbapenems | |
| Enterobacteriaceae Infections | |
| Heterocyclic Compounds, 1-Ring |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Melinta Therapeutics | PubMed |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28039276 | The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28039276 | PubMed |
| 2 | 26926624 | Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/26926624 | PubMed |
| 3 | 15561842 | Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/15561842 | PubMed |
| 4 | 30020449 | Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30020449 | PubMed |
| 5 | 34430671 | Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34430671 | PubMed |
| 6 | 33318006 | Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33318006 | PubMed |
| 7 | 32151332 | Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. | Lancet Infect Dis | 2020 | https://conductscience.org/library/papers/32151332 | PubMed |
| 8 | 35976531 | Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study. | Infect Dis Ther | 2022 | https://conductscience.org/library/papers/35976531 | PubMed |
| 9 | 30219824 | Renal Dosing of Antibiotics: Are We Jumping the Gun? | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30219824 | PubMed |
| 10 | 30270406 | Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. | Infect Dis Ther | 2018 | https://conductscience.org/library/papers/30270406 | PubMed |
| 11 | 24867993 | Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24867993 | PubMed |
| 12 | 26125030 | Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. | Open Forum Infect Dis | 2015 | https://conductscience.org/library/papers/26125030 | PubMed |
| 13 | 16251324 | Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16251324 | PubMed |
| 14 | 32755654 | Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/32755654 | PubMed |
| 15 | 36374023 | Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36374023 | PubMed |
| 16 | 29133570 | Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29133570 | PubMed |
| 17 | 24970941 | Time to Administration of Antibiotics among Inpatients with Severe Sepsis or Septic Shock. | Can J Hosp Pharm | 2014 | https://conductscience.org/library/papers/24970941 | PubMed |
| 18 | 36968951 | Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/36968951 | PubMed |
| 19 | 32015049 | Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32015049 | PubMed |
| 20 | 29507064 | Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29507064 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41258724
GET https://conductscience.org/api/papers/v1/41258724/references?page=2